CareDx Raises 2026 Revenue and Adjusted EBITDA Guidance
CareDx raised its 2026 revenue guidance to $520 million-$530 million and adjusted EBITDA guidance to $90 million-$100 million.
Related stories
FTSE 100 Rises Led by Astra & BP
The FTSE 100 rose 0.5% on Friday, outperforming global markets amid a tech-led selloff, as strong earnings from heavyweight stocks AstraZeneca and BP supported the index. AstraZene
H impact | EARNINGS | Oct 30, 2026, 08:56 AM UTC
FTSE MIB Decline
Milan’s FTSE MIB fell over 1% to around 49,500 on Friday, snapping a five-day winning streak as weakness in technology stocks weighed on the index. Concerns over returns from massi
L impact | EARNINGS | Oct 30, 2026, 08:48 AM UTC
European Stocks Fall as Tech Weighs
European stocks traded in negative territory on Friday, with the STOXX 50 falling 0.7% and the STOXX 600 slipping 0.2%. The European technology sector joined a global sell-off foll
H impact | EARNINGS | Oct 30, 2026, 08:44 AM UTC
Amazon’s Third-Quarter Profit Falls, Missing Wall Street Expectations
Amazon reported lower profit in the third quarter, missing Wall Street expectations.
M impact | EARNINGS | Oct 30, 2026, 08:44 AM UTC
Puma Narrows 2026 Operating Loss Guidance as Quarterly Sales Top Market View
M impact | EARNINGS | Oct 30, 2026, 08:38 AM UTC
AstraZeneca Reports Results for Quarter Ended September 30
M impact | EARNINGS | Oct 30, 2026, 08:37 AM UTC